Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary percutaneous hepatic perfusion (PHP(TM)) system for the treatment of cancers of the liver, announced today that it has achieved the seventy-five percent enrollment point of its pivotal Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The participating cancer centers in this trial continue to evaluate and enroll patients and the Company remains on target to complete enrollment this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO)

Commenting on this important event, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "Reaching the seventy-five percent enrollment point represents a significant milestone for our Company as we continue to accelerate this trial and accrue the data to support FDA approval of the Delcath PHP System(TM). Our effort to expand the trial to leading cancer centers has produced the accelerated pace that delivers this milestone just months after hitting 50% accrual and we look forward to completing enrollment this year. The clinical data for the first 69 patients will be submitted to the Data Safety Monitoring Board for evaluation once we complete the collection of follow-up data on the recently randomized patients. We look forward to updating our investors at our annual meeting to be held on June 9th."

This multi-center clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under this CRADA, patients for this study are being treated at the NCI and at top cancer centers throughout the United States. The NCI is serving as coordinating center for the study, which includes the initiation and training of the new clinical trial centers for this important trial. Plans under the CRADA include continuing patient enrollments and completing the clinical testing of PHP as treatment for a number of life threatening liver diseases.

The Phase III Study

The Phase III study is testing Delcath's PHP(TM) System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... NEW YORK , May 23, 2016 /PRNewswire/ ... Mass Spectrometry Market Size, Share, Development, Growth and ... Platform (Hybrid, Single and Other), by Application (Drug ... Others), by End Users (Pharmaceuticals, Life Science and ... Published by P&S Market Research, the global ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended Use of ... 13 years, and above. Effective immediately, the PrePex device, manufactured ... males in the 14 priority countries in Southern and ... circumcision device to receive WHO Prequalification on 31 May 2013. ... " The expanded use of PrePex for younger ...
(Date:5/23/2016)... 2016 Experts from various countries ... and the role of technology in innovative healthcare ... The First International Conference of VPS-Penn Medicine opened in ... presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister of ... which helps provide personalized medicine and tailor-made healthcare in disease ...
Breaking Medicine Technology:
(Date:5/25/2016)... Texas (PRWEB) , ... May 25, 2016 , ... The ... Myers Veterans Biomedical Technology Program to help provide veterans a pathway to employment and ... Executive, presented a $20,000 check to Nick Hallack, President and CEO of Medisend, parent ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... International University (FIU) Herbert Wertheim College of Medicine announced the AUA-FIU Global MD ... Degree and Global Health Certificate from AUA and a Certificate of Completion from ...
(Date:5/25/2016)... O'Fallon, MO (PRWEB) , ... May 25, 2016 , ... ... located in Woodlawn Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients ... and cosmetic treatments . Dr. Schwarz’s success is reflected in the superior ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading destination ... innovative workshops and training opportunities in the growing field of yoga therapy ... who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic health ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of ... McKenna ran one of Allstate’s most successful agencies for 48 years, but it was ... The award named for him is not given every year, but only when an ...
Breaking Medicine News(10 mins):